Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Palantirs Q3 earnings and guidance are the dominant focus, with traders debating whether results can clear a high bar as AI stocks face a broader repricing. Bulls expect continued growth and an outlook increase, while bears argue that even a beat may not support the valuation without stronger guidance.

CASHCATs volatile rally and repeated pushes toward record highs are driving attention, with traders debating whether pullbacks are buying opportunities or signs of a pump-and-dump. Bulls cite Robinhood-chain activity and token burns as potential support, but those claims remain speculative amid concerns about sharp selloffs and weak support.

Broadcom is caught in a semiconductor selloff as traders question whether massive hyperscaler AI spending can generate adequate returns, raising concerns about capex cuts and the companys reliance on a small group of large customers. Some see the decline as indiscriminate sector selling despite continued AI investment and Broadcoms role as a chip supplier, while others worry that financing arrangements and customer concentration add risk.

Hyperliquids rally and repeated tests of record levels have traders focused on a push toward the $100 mark. Bulls point to fee-funded HYPE buybacks and growing institutional or regulated-market access as support for the tokens market story, while others warn of pullbacks and selling pressure.

Oracles sharp selloff and failure to hold a rally after its Investor Day update are fueling debate over its debt-funded AI data-center expansion, heavy capital spending, and whether its large backlog will convert into cash flow. Bulls point to managements cash-flow and spending plans as evidence of a path forward, while bears remain concerned about financing risk and AI demand, with weakness in other major tech stocks adding pressure.

Salesforce is caught in the broader debate over whether AI agents will weaken seat-based SaaS software or deepen reliance on established enterprise platforms. Traders connect pressure on CRM to sector-wide software weakness, including spillover from ServiceNow, while others see the pullback as an opportunity and argue Salesforces entrenched workflows can adapt to AI.

Anticipation of QUILT-2.005 Phase 3 results for ANKTIVA plus BCG in BCG-nave bladder cancer dominates discussion, alongside hopes that quarterly results will show continued commercial growth. Many traders see the data as a potential path to broader use after ANKTIVAs expanded bladder-cancer approval, while others question the efficacy outlook and competition; short-squeeze claims remain speculative.

A SemiVision observers claim that POET optical hardware appeared in Foxconns photonics ecosystem at Hon Hai Tech Day is fueling speculation that the FIT relationship is progressing and could lead to orders. Traders see it as technical validation, but others stress that a demo does not confirm commercial shipments or purchase orders and are looking to upcoming results for evidence of execution.

Binances reported major security breach is weighing on crypto sentiment, with traders debating whether renewed withdrawal and trust concerns could extend selling across ETH and the broader market. Some see the selloff as a buying opportunity and distinguish an exchange breach from a failure of Ethereum itself, while others warn of further downside.

Zevra is drawing attention around its Q3 results and the pending CHMP re-examination of MIPLYFFA for Niemann-Pick type C, with FDA feedback on celiprolol also viewed as a potential catalyst. Traders are weighing confidence in U.S. commercial growth against skepticism about a favorable European regulatory outcome and concerns about management execution.